Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Music Experts Visit 'Spring Bud Dream Chorus' in HubeiFuzhou in SE China to Mark Int'l Museum DayChina Moves to Boost Traditional Chinese Medicine CulturePolicy Seeks to Improve Students' Science LiteracyMaternal, Infant Mortality Rates in China Drop to Historic LowsGreen Rural Revival Program Lifts Image of Countryside in China's ZhejiangCultural and Creative Products Showcased at Metro Station in N ChinaChina Enhances Judicial Protection for Minors Against Sexual ViolationsVillage Basketball Competition Kicks off in SW China's GuizhouChina's Top Procuratorate Promotes Law's Implementation
2.7615s , 6515.1015625 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Global Gazetteer news portal